My favorite metric lately has been the % of vaccinated people in the country. Initially the CDC says 18 and over. When the country got to around 65% the FDA approved vaccines for 16 and over and the counties % goes down. When the % got to around 65% of those 16 and older the FDA approves the vaccine for 12-15 and the % goes down. Now the US is at around 65% vaccinated for 12 and older and the approval for children is right around the corner so the US can feel perpetually way behind in vaccination % numbers so the local, state and federal governments can continue to tighten the screws on folks like myself who have yet to take the vaccine and no one really cares. This is fucking nuts.
Ivermectin is the bad horse medicine. The new Merck drug is the good horse medicine, just 16 times as expensive as the US government played hardball with Merck and went to the mat on the price negotiation.
Merck Charging US 40 Times What It Costs To Make Govt-Financed COVID Pill
BY TYLER DURDEN WEDNESDAY, OCT 06, 2021 - 07:00 AM Merck's new 'not Ivermectin' Covid-19 treatment, molnupiravir, costs $17.74 to produce - yet the company is charging the US government $712 for the treatment - a 40x markup, according to The Intercept, citing a report issued last week by the Harvard School of Public Health and King’s College Hospital in London.
The pill, originally developed using US government funds as a possible treatment for Venezuelan equine encephalitis, cut the risk of hospitalization and death in half in a randomized trial of 775 adults with mild/moderate Covid who were considered at high risk for disease due to comorbidities such as obesity, diabetes and heart disease. The trial was stopped early so the company could apply for and emergency use authorization (EUA). The drug did not benefit patients who were already hospitalized with severe disease.
Yet, as Quartz points out, only Merck and Ridgeback will profit from the new antiviral - which they say "could be one of the most lucrative drugs ever," bringing in as much as $7 billion by the end of this year alone.
Despite its initial investment, the U.S. government seems to be facing a steep markup in prices. In June, the government signed a $1.2 billion contract with Merck to supply 1.7 million courses of the medication at the $712 price. The transaction is due to take place as soon as molnupiravir receives emergency use authorization from the Food and Drug Administration.
Good government advocates are pointing out that because federal agencies spent at least $29 million on the drug’s development, the government has the obligation to ensure that the medicine is affordable. “The public funded this drug, and therefore the public has some rights, including the rights you have it available under reasonable terms,” said Luis Gil Abinader, senior researcher at Knowledge Ecology International. -The Intercept ...
If only there were another option for mild-moderate Covid-19 cases that was inexpensive and used around the world for decades with an extremely positive drug safety profile.
We're just going to leave this here (as we noted last month):
Widely prescribed anti-parasitic Ivermectin (also made by Merck) has shown massive efficacy worldwide in the treatment of mild and moderate cases of Covid-19, plus as a prophylactic. India's Uttar Pradesh province, with a population of over 200 million, says that widespread early use of Ivermectin 'helped keep positivity [and] deaths low.'
Ivermectin is the bad horse medicine. The new Merck drug is the good horse medicine, just 16 times as expensive as the US government played hardball with Merck and went to the mat on the price negotiation.
Merck Charging US 40 Times What It Costs To Make Govt-Financed COVID Pill
BY TYLER DURDEN WEDNESDAY, OCT 06, 2021 - 07:00 AM Merck's new 'not Ivermectin' Covid-19 treatment, molnupiravir, costs $17.74 to produce - yet the company is charging the US government $712 for the treatment - a 40x markup, according to The Intercept, citing a report issued last week by the Harvard School of Public Health and King’s College Hospital in London.
The pill, originally developed using US government funds as a possible treatment for Venezuelan equine encephalitis, cut the risk of hospitalization and death in half in a randomized trial of 775 adults with mild/moderate Covid who were considered at high risk for disease due to comorbidities such as obesity, diabetes and heart disease. The trial was stopped early so the company could apply for and emergency use authorization (EUA). The drug did not benefit patients who were already hospitalized with severe disease.
Yet, as Quartz points out, only Merck and Ridgeback will profit from the new antiviral - which they say "could be one of the most lucrative drugs ever," bringing in as much as $7 billion by the end of this year alone.
Despite its initial investment, the U.S. government seems to be facing a steep markup in prices. In June, the government signed a $1.2 billion contract with Merck to supply 1.7 million courses of the medication at the $712 price. The transaction is due to take place as soon as molnupiravir receives emergency use authorization from the Food and Drug Administration.
Good government advocates are pointing out that because federal agencies spent at least $29 million on the drug’s development, the government has the obligation to ensure that the medicine is affordable. “The public funded this drug, and therefore the public has some rights, including the rights you have it available under reasonable terms,” said Luis Gil Abinader, senior researcher at Knowledge Ecology International. -The Intercept ...
If only there were another option for mild-moderate Covid-19 cases that was inexpensive and used around the world for decades with an extremely positive drug safety profile.
We're just going to leave this here (as we noted last month):
Widely prescribed anti-parasitic Ivermectin (also made by Merck) has shown massive efficacy worldwide in the treatment of mild and moderate cases of Covid-19, plus as a prophylactic. India's Uttar Pradesh province, with a population of over 200 million, says that widespread early use of Ivermectin 'helped keep positivity [and] deaths low.'
The Cartel seeks to keep all of its members happy. Some get to produce the vaccines, others get to produce treatments. All beaks get wet.
Comments
Open up by Easter
If it saved one grandma or grandpa! Never let yourself forget that the left in this country are mentally unstable. Twitter is their baseline.
But ghe hospitals are over-flowing with unvaxxed horse-paste eaters!
Get the Jab, you Murderers!
https://www.zerohedge.com/covid-19/merck-charging-us-40-times-what-it-costs-make-govt-financed-covid-pill
Merck Charging US 40 Times What It Costs To Make Govt-Financed COVID Pill
BY TYLER DURDEN
WEDNESDAY, OCT 06, 2021 - 07:00 AM
Merck's new 'not Ivermectin' Covid-19 treatment, molnupiravir, costs $17.74 to produce - yet the company is charging the US government $712 for the treatment - a 40x markup, according to The Intercept, citing a report issued last week by the Harvard School of Public Health and King’s College Hospital in London.
The pill, originally developed using US government funds as a possible treatment for Venezuelan equine encephalitis, cut the risk of hospitalization and death in half in a randomized trial of 775 adults with mild/moderate Covid who were considered at high risk for disease due to comorbidities such as obesity, diabetes and heart disease. The trial was stopped early so the company could apply for and emergency use authorization (EUA). The drug did not benefit patients who were already hospitalized with severe disease.
Yet, as Quartz points out, only Merck and Ridgeback will profit from the new antiviral - which they say "could be one of the most lucrative drugs ever," bringing in as much as $7 billion by the end of this year alone.
Despite its initial investment, the U.S. government seems to be facing a steep markup in prices. In June, the government signed a $1.2 billion contract with Merck to supply 1.7 million courses of the medication at the $712 price. The transaction is due to take place as soon as molnupiravir receives emergency use authorization from the Food and Drug Administration.
Good government advocates are pointing out that because federal agencies spent at least $29 million on the drug’s development, the government has the obligation to ensure that the medicine is affordable. “The public funded this drug, and therefore the public has some rights, including the rights you have it available under reasonable terms,” said Luis Gil Abinader, senior researcher at Knowledge Ecology International. -The Intercept ...
If only there were another option for mild-moderate Covid-19 cases that was inexpensive and used around the world for decades with an extremely positive drug safety profile.
We're just going to leave this here (as we noted last month):
Widely prescribed anti-parasitic Ivermectin (also made by Merck) has shown massive efficacy worldwide in the treatment of mild and moderate cases of Covid-19, plus as a prophylactic. India's Uttar Pradesh province, with a population of over 200 million, says that widespread early use of Ivermectin 'helped keep positivity [and] deaths low.'
Merck is following the P&G model. "No, don't use that- it's not as good....use this NEW stuff that costs twice as much because pods > powder"
Like the old Tide doesn't work getting clothes clean.
I hate to go all Godwin here but that's pretty tone deaf
At best
Fucking krauts